These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8891152)

  • 21. Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses.
    Chang S; Zhuang D; Li J; Liu S; Li H; Han J; Li L; Liu Y; Bao Z; Li T; Song H; Zhang W
    Int J Infect Dis; 2015 Aug; 37():86-92. PubMed ID: 26117343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel recombinant phenotypic assay for clonal analysis of reverse transcriptase mutations conferring drug resistance to HIV-1 variants.
    Paolucci S; Baldanti F; Zavattoni M; Gerna G
    J Antimicrob Chemother; 2004 May; 53(5):766-71. PubMed ID: 15044427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
    Shafer RW; Eisen JA; Merigan TC; Katzenstein DA
    J Virol; 1997 Jul; 71(7):5441-8. PubMed ID: 9188616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1.
    Vega Y; Pérez-Alvárez L; Delgado E; Muñoz M; Casado G; Carmona R; Sierra M; Vázquez de Parga E; Pinilla M; García V; Medrano L; Contreras G; Thomson M; Nájera R
    J Clin Microbiol; 2005 Oct; 43(10):5301-4. PubMed ID: 16208003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility.
    Bulgheroni E; Croce F; Citterio P; Viganò O; Visonà R; Sala E; Galli M; Rusconi S
    J Clin Virol; 2004 Jan; 29(1):27-32. PubMed ID: 14675866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC).
    García Lerma J; Schinazi RF; Juodawlkis AS; Soriano V; Lin Y; Tatti K; Rimland D; Folks TM; Heneine W
    Antimicrob Agents Chemother; 1999 Feb; 43(2):264-70. PubMed ID: 9925516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.
    Frankel FA; Marchand B; Turner D; Götte M; Wainberg MA
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2657-64. PubMed ID: 15980333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
    Clarke JR; Kaye S; Babiker AG; Hooker MH; Tedder R; Weber JN
    J Virol Methods; 2000 Aug; 88(2):117-24. PubMed ID: 10960699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals.
    Ribas SG; Ondoa P; Schüpbach J; van der Groen G; Fransen K
    J Virol Methods; 2003 Oct; 113(1):29-34. PubMed ID: 14500124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.